JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Seroprevalence of Anti-EBV IgG among Various Age Groups from Khon Kaen Province, Thailand
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Seroprevalence of Anti-EBV IgG among Various Age Groups from Khon Kaen Province, Thailand
Suntornlohanakul, Rabporn; Wanlapakorn, Nasamon; Vongpunsawad, Sompong; Thongmee, Thanunrat; Chansaenroj, Jira; Poovorawan, Yong;
  PDF(new window)
 Abstract
Epstein-Barr virus (EBV) is an extremely common herpesvirus that may cause asymptomatic infection or various diseases, including infectious mononucleosis, certain lymphoproliferative diseases and several types of neoplasms. Vaccine development is an important strategy to reduce the burden of EBV-associated diseases and the timing of vaccinations should be before primary infection occurs. In the past, more than 90% of Thai children were infected with EBV in early childhood. Now, due to the improved healthcare system in Thailand, we aim to determine current prevalence of EBV infection among people in different age groups. A total of 538 sera were collected from residents of Khon Kaen province in northeastern Thailand for detecting anti-EBV IgG. Sera of infants under 2-years-old were also tested for anti-EBV IgM and EBV-DNA. The prevalence of anti-EBV IgG was 47.1% (95% CI: 23.3-70.8) in infants aged 0-6 months, 34.9% (95% CI: 23.1-46.7) in those aged 6-24 months, 87.9% (95% CI: 79.5-96.3) in children aged 3-5 years and then maintained at above 95% through adulthood. These seropositivity rates among Thai children remain similar to those found in a previous study conducted 20 years ago. Thai children are still exposed to EBV from an early age. Therefore, a prophylactic vaccine should be given within the first two years of life.
 Keywords
Seroprevalence;anti-EBV IgG;children;adult;Thailand;
 Language
English
 Cited by
 References
1.
Balfour HH Jr (2014). Progress, prospects, and problems in Epstein-Barr virus vaccine development. Curr Opin Virol, 6, 1-5. crossref(new window)

2.
Balfour HH Jr, Sifakis F, Sliman JA, et al (2013). Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6-19 years in the United States and factors affecting its acquisition. J Infect Dis, 208, 1286-93. crossref(new window)

3.
Biggar RJ, Henle W, Fleisher G, et al (1978). Primary Epstein- Barr virus infections in African infants. I. Decline of maternal antibodies and time of infection. Int J Cancer, 22, 239-43. crossref(new window)

4.
Chan KH, Tam JS, Peiris JS, et al (2001). Epstein-Barr virus (EBV) infection in infancy. J Clin Virol, 21, 57-62. crossref(new window)

5.
Chatproedprai S, Chongsrisawat V, Chatchatee P, et al (2007). Declining trend in the seroprevalence of infection with hepatitis A virus in Thailand. Ann Trop Med Parasitol, 101, 61-8. crossref(new window)

6.
Chen CY, Huang KY, Shen JH, et al (2015). A large-scale seroprevalence of epstein-barr virus in taiwan. PLoS One, 10, 115836.

7.
Cheng CC, Chang LY, Shao PL, et al (2007). Clinical manifestations and quantitative analysis of virus load in Taiwanese children with Epstein-Barr virus-associated infectious mononucleosis. J Microbiol Immunol Infect, 40, 216-21.

8.
Cohen JI, Bollard CM, Khanna R, et al (2008). Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBVassociated lymphomas. Leuk Lymphoma, 49, 27-34.

9.
Condon LM, Cederberg LE, Rabinovitch MD, et al (2014). Agespecific prevalence of Epstein-Barr virus infection among Minnesota children: effects of race/ethnicity and family environment. Clin Infect Dis, 59, 501-8. crossref(new window)

10.
De Paschale M, Clerici P (2012). Serological diagnosis of Epstein-Barr virus infection: Problems and solutions. World J Virol, 1, 31-43. crossref(new window)

11.
Dohno S, Maeda A, Ishiura Y, et al (2010). Diagnosis of infectious mononucleosis caused by Epstein-Barr virus in infants. Pediatr Int, 52, 536-40. crossref(new window)

12.
Dowd JB, Palermo T, Brite J, et al (2013). Seroprevalence of Epstein-Barr virus infection in U.S. children ages 6-19, 2003-2010. PLoS One, 8, 64921. crossref(new window)

13.
Haque T, Iliadou P, Hossain A, et al (1996). Seroepidemiological study of Epstein-Barr virus infection in Bangladesh. J Med Virol, 48, 17-21. crossref(new window)

14.
Hjalgrim H, Askling J, Sorensen P, et al (2000). Risk of Hodgkin's disease and other cancers after infectious mononucleosis. J Natl Cancer Inst, 92, 1522-8. crossref(new window)

15.
Hsu JL, Glaser SL (2000). Epstein-barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev Oncol Hematol, 34, 27-53. crossref(new window)

16.
Kangro HO, Osman HK, Lau YL, et al (1994). Seroprevalence of antibodies to human herpesviruses in England and Hong Kong. J Med Virol, 43, 91-6. crossref(new window)

17.
Kimura H, Ito Y, Suzuki R, et al (2008). Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease. Rev Med Virol, 18, 305-19. crossref(new window)

18.
Leogrande G, Jirillo E (1993). Studies on the epidemiology of child infections in the Bari area (south Italy). VII. Epidemiology of Epstein-Barr virus infections. Eur J Epidemiol, 9, 368-72. crossref(new window)

19.
Mekmullica J, Kritsaneepaiboon S, Pancharoen C (2003). Risk factors for Epstein-Barr virus infection in Thai infants. Southeast Asian J Trop Med Public Health, 34, 395-7.

20.
Mitarnun W, Pradutkanchana J, Ishida T (2004). Epstein-Barr virus-associated nodal malignant lymphoma in Thailand. Asian Pac J Cancer Prev, 5, 268-72.

21.
Nystad TW, Myrmel H (2007). Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM-and EBNA-1-antibodies and suspected infectious mononucleosis. J Clin Virol, 38, 292-7. crossref(new window)

22.
Pancharoen C, Bhattarakosol P, Thisyakorn U. Seroprevalence of Epstein-Barr virus infection in Thai children. J Med Assoc Thai, 84, 850-4.

23.
Pancharoen C, Mekmullica J, Chinratanapisit S, et al (2001). Antibody among children in various age groups in Bangkok, Thailand. Asian Pac J Allergy Immunol, 19, 135-7.

24.
Piriou E, Asito AS, Sumba PO, et al (2012). Early age at time of primary Epstein-Barr virus infection results in poorly controlled viral infection in infants from Western Kenya: clues to the etiology of endemic Burkitt lymphoma. J Infect Dis, 205, 906-13. crossref(new window)

25.
Poovorawan Y, Tantimongkolsuk C, Chongsrisawat V, et al (1997). High prevalence of Epstein-Barr virus antibody among school children of the low to middle socio-economic class in Bangkok, Thailand. Southeast Asian J Trop Med Public Health, 28, 434-5.

26.
Sakulwira K, Theamboonlers A, Oraveerakul K, et al (2004). Orangutan herpesvirus. J Med Primatol, 33, 25-9. crossref(new window)

27.
Sokal EM, Hoppenbrouwers K, Vandermeulen C, et al (2007). Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis, 196, 1749-53. crossref(new window)

28.
Takeuchi K, Tanaka-Taya K, Kazuyama Y, et al (2006). Prevalence of Epstein-Barr virus in Japan: Trends and future prediction. Pathol Int, 56, 112-6. crossref(new window)

29.
Tiwawech D, Srivatanakul P, Karalak A, et al (2005). Glutathione S-transferase M1 gene polymorphism in Thai nasopharyngeal carcinoma. Asian Pac J Cancer Prev, 6, 270-5.

30.
VanDevanter DR, Warrener P, Bennett L, et al (1996). Detection and analysis of diverse herpesviral species by consensus primer PCR. J Clin Microbiol, 34, 1666-71.

31.
Xiong G, Zhang B, Huang MY, et al (2014). Epstein-Barr virus (EBV) infection in Chinese children: a retrospective study of age-specific prevalence. PLoS One, 9, e99857. crossref(new window)

32.
Yuan Huang, Cong Wei, Kun Zheng, et al (2013). The impact of serological features in Chinese children with primary or past Epstein-Barr virus infections. Virol J, 10, 55. crossref(new window)